Patent application number | Description | Published |
20080242610 | POLYPEPTIDES COMPRISING FAS ACTIVATION AND NKG2D-LIGAND DOMAINS - The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer. | 10-02-2008 |
20090081789 | Activation of nuclear factor kappa B - The present invention describes a method for targeting a tumor cell comprising contacting the tumor cell with a composition comprising a macrophage and a factor that upregulates nuclear factor-kappa B (NFκB) activity. | 03-26-2009 |
20090117658 | Macrophage transfection method - Described are a method and a composition for transfecting monocytes, as well as use of the same for therapeutic purposes. The composition is composed of a nucleic acid component, a lysosome evading component and a digestible particle that can be phagocytized. Preferably, the monocyte is a macrophage and the digestible particle is from a natural source, such as from a microbial source. More preferably, the digestible particle is a yeast cell wall particle such as zymosan. The composition itself, or cells pretreated with the composition, are useful in all gene medicine applications, such as gene therapy, gene vaccination, cancer treatment as well as immunomodulation and tissue repair. | 05-07-2009 |
20100111985 | VACCINE COMPOSITIONS AND METHODS OF USE - Described are a method and a composition for delivery of a protein to an antigen presenting cell. The composition is composed of a polypeptide component, a buffering component and a particle to be phagocytized. In one embodiment, the antigen presenting cell is aa macrophage or a dendritic cell and the particle to be phagocytized is from a natural source, such as from a microbial source. The composition itself, or cells pretreated with the composition, are useful for strategies in vaccine development. | 05-06-2010 |
20100284975 | POLYPEPTIDES COMPRISING FAS ACTIVATION AND NKG2D-LIGAND DOMAINS - The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer. | 11-11-2010 |
20130131640 | METHOD OF CREATING AND SORTING FUSED CELLS - An efficient and simplified method for preparing and sorting fused cells is described herein. This approach yields fused cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system. | 05-23-2013 |
20140065173 | TUMOR LYSATE LOADED PARTICLES - Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma. | 03-06-2014 |
20140065190 | TUMOR LYSATE LOADED PARTICLES - Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma. | 03-06-2014 |
20140161912 | COMPOSITIONS AND METHODS FOR TISSUE REGENERATION - Methods and compositions using an orthosilicate for tissue regeneration, such as to treat a disease or condition, are described, including on the skin. Also described are methods for making such compositions. | 06-12-2014 |
20140248316 | HYBRID CELLS FOR TREATING CANCER PATIENTS - The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation. | 09-04-2014 |